Invention Grant
- Patent Title: Therapy and new therapeutic agent for blood cancer
-
Application No.: US17424805Application Date: 2020-07-17
-
Publication No.: US11957701B2Publication Date: 2024-04-16
- Inventor: Tatsuhiro Ishida , Kiyoshi Eshima
- Applicant: Delta-Fly Pharma, Inc.
- Applicant Address: JP Tokushima
- Assignee: Delta-Fly Pharma, Inc.
- Current Assignee: Delta-Fly Pharma, Inc.
- Current Assignee Address: JP Tokushima
- Agency: Foley & Lardner LLP
- International Application: PCT/JP2020/027749 2020.07.17
- International Announcement: WO2022/014025A 2022.01.20
- Date entered country: 2021-07-21
- Main IPC: A01N43/04
- IPC: A01N43/04 ; A61K31/635 ; A61K31/70 ; A61K31/7068 ; A61P35/02
Abstract:
An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.
Public/Granted literature
- US20220313718A1 NEW THERAPY AND NEW THERAPEUTIC AGENT FOR BLOOD CANCER Public/Granted day:2022-10-06
Information query
IPC分类:
